Why carry out this study?

Real-world studies assessing the long-term effectiveness of galcanezumab in migraine prevention are limited. The REALITY study thus aimed to provide an understanding of the long-term effectiveness of galcanezumab among patients with migraine in Italy,

The effect of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis was studied.

What was learned from the study?

The results of the study confirmed that galcanezumab has a rapid onset of effect and provides a long-term response, including reduction in the number of migraines monthly, improvement in migraine-related disability, and reduction in healthcare resource use.

Maintenance of galcanezumab effect was observed with continued use, and previous treatment failures were associated with low response rate.

Patients in the REALITY study were the very first patients to be treated with galcanezumab in the real-world setting in Italy (prior to the Italian Medicines Agency’s establishment of criteria for reimbursement)